ASXL1 mutations occur in 5–10% of patients with ET or PV, 20–45% of patients with PMF and 10–25% of patients with SMF [58,59,60,62,63,64,65,67,68,75]. This evidence concerns the gene ASXL1 and essential thrombocythemia.